Washington Univ School of Medicine
Welcome,         Profile    Billing    Logout  
 17 Trials 
49 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gauvain, Karen
NCT02962167: Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT

Completed
1
34
US
Modified Measles Virus, MV-NIS, Modified Measles Virus Lumbar Puncture, MV-NIS LP
Sabine Mueller, MD, PhD, No More Kids With Cancer, The Matthew Larson Foundation for Pediatric Brain Tumors, Vyriad, Inc., Mayo Clinic
Medulloblastoma, Childhood, Recurrent, Atypical Teratoid/Rhabdoid Tumor, Medulloblastoma Recurrent
05/23
05/23
Khosroshahi, Arezou
SIRIUS-SLE 2, NCT05624749 / 2022-002690-29: Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus

Recruiting
3
280
Europe, US, RoW
ianalumab, VAY736, placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Systemic Lupus Erythematosus
01/27
01/29
NCT05000216: COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

Completed
2
257
US
Moderna mRNA-1273, mRNA-1273 vaccine (Moderna), Moderna COVID-19 Vaccine, SARS-CoV-2 RNA vaccine, COVID-19 vaccine, BNT162b2, mRNA-1273 vaccine (Pfizer/BioNTech), Pfizer-BioNTech COVID-19 vaccine, Ad26.COV2.S, Janssen COVID-19 Vaccine, JNJ-78436735, Continue IS (MMF or MPA), immunosuppressive medication, mycophenolate mofetil, MMF, CellCept®, mycophenolic acid, MPA, Continue IS (MTX), methotrexate, MTX, Continue IS (B cell depletion therapy), mAbs targeting CD19 or CD20, anti-BAFF mAb, Monovalent [B.1.351] CoV2 preS dTM-AS03, Sanofi-GSK COVID-19 Vaccine, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, mRNA-1273 vaccine (Moderna), Bivalent, Moderna COVID-19 Vaccine, Bivalent, SARS-CoV-2 RNA vaccine, Bivalent, COVID-19 vaccine, Bivalent, BNT162b2, Bivalent, mRNA-1273 vaccine (Pfizer/BioNTech), Bivalent, Pfizer-BioNTech COVID-19 vaccine, Bivalent
National Institute of Allergy and Infectious Diseases (NIAID), Autoimmunity Centers of Excellence, Rho Federal Systems Division, Inc.
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
06/23
03/24
NCT02633163: Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)

Recruiting
2
81
US
Low Dose Mesenchymal Stem Cells (MSCs), High Dose Mesenchymal Stem Cells (MSCs), Placebo Infusion
Medical University of South Carolina
Systemic Lupus Erythematosus
12/24
06/25
DIVERT, NCT05306873: Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus

Terminated
2
9
US
Mycophenolate Mofetil, CellCept, MMF, Placebo for Mycophenolate Mofetil, Voclosporin, Lupkynis, Lupkynis(TM), Placebo for Voclosporin
National Institute of Allergy and Infectious Diseases (NIAID)
Systemic Lupus Erythematosus
04/24
04/24
VIBRANT, NCT05201469: VIB4920 for Active Lupus Nephritis

Recruiting
2
74
US
VIB4920, Placebo for VIB4920
National Institute of Allergy and Infectious Diseases (NIAID)
Lupus Nephritis
08/26
03/27
NCT04918147: Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)

Terminated
2
8
US
elotuzumab, BMS-901608, Empliciti®, placebo for elotuzumab, normal saline, methylprednisolone, Solu-Medrol®, diphenhydramine, Benadryl®, acetaminophen, Tylenol®, famotidine, H2 blocker, prednisone, corticosteroid
National Institute of Allergy and Infectious Diseases (NIAID), Autoimmunity Centers of Excellence, Bristol-Myers Squibb, Rho Federal Systems Division, Inc.
IgG4 Related Disease, IgG4-RD
01/24
01/24
RESET-SLE, NCT06121297: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

Recruiting
1/2
12
Europe, US
CABA-201
Cabaletta Bio
Systemic Lupus Erythematosus, Lupus Nephritis
12/27
12/27
GLEAM, NCT06294236: Study Evaluating SC291 in Subjects with Severe R/r B-cell Mediated Autoimmune Diseases

Recruiting
1
36
US
SC291, Cyclophosphamide, Fludarabine
Sana Biotechnology
Lupus Erythematosus, Systemic Lupus Erythematosus, SLE (Systemic Lupus), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Granulomatous Polyangiitis, Microscopic Polyangiitis
12/27
03/28
NCT05934149: Lupus Landmark Study: A Prospective Registry and Biorepository

Recruiting
N/A
3500
Canada, US
Lupus Research Alliance
Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Neuropsychiatric Systemic Lupus Erythematosus
12/33
12/33
Klebert, Michael K
NCT06020118: Comparative Immunogenicity of Concomitant vs Sequential mRNA COVID-19 and Influenza Vaccinations

Completed
4
455
US
Simultaneous Vaccination (Influenza Vaccine and mRNA COVID booster), Sequential Vaccination (Influenza vaccine then mRNA COVID booster), Sequential Vaccination (mRNA COVID booster then Influenza vaccine)
Duke University, Centers for Disease Control and Prevention, Arizona State University, University Hospitals Cleveland Medical Center, University of Pittsburgh, Washington University School of Medicine, Valleywise Health, VA Northeast Ohio Health Care, Senders Pediatrics
Influenza, COVID-19
03/24
05/24
NCT04636437: Doravirine for Persons With Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide

Active, not recruiting
4
222
US
Doravirine 100 Mg, Tenofovir alafenamide/emtricitabine, tenofovir alafenamide/lamivudine, Integrase strand transfer inhibitors, tenofovir disproxil fumarate/emtricitabine, tenofovir disproxil fumarate/lamivudine
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
11/24
11/24
NCT06518577: Immunogenicity of Influenza Vaccinations

Active, not recruiting
4
605
US
Flucelvax (ccIIV4), Flublok (RIV) or Fluzone (IIV)
Duke University, Centers for Disease Control and Prevention, Arizona State University, University Hospitals Cleveland Medical Center, University of Pittsburgh, Washington University School of Medicine, VA Medical Center-Cleveland
Influenza
12/24
05/25
BEe-HIVe, NCT04193189: B-Enhancement of HBV Vaccination in Persons Living With HIV (): Evaluation of HEPLISAV-B

Completed
3
640
US, RoW
HEPLISAV-B, ENGERIX-B
National Institute of Allergy and Infectious Diseases (NIAID), Dynavax Technologies Corporation
HIV Infection, Hepatitis B
08/24
08/24
NCT03635788: The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE

Active, not recruiting
3
310
US
Standard of Care (SOC) Oral ART, Oral RPV, Rilpivirine, Oral CAB, Cabotegravir, GSK1265744, RPV-LA Loading Dose, Rilpivirine Long-Acting Injectable, CAB-LA Loading Dose, Cabotegravir Long-Acting Injectable, RPV-LA Maintenance Dose, CAB-LA Maintenance Dose
National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare
HIV Infections
11/24
08/26
NCT05630885: A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV

Completed
2
110
US
CVC 150 mg, CVC 300 mg, Placebo for CVC 150 mg, Placebo for CVC 300 mg
National Institute of Allergy and Infectious Diseases (NIAID), AbbVie
HIV-1-infection
06/24
06/24
NCT06705478: Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV

Not yet recruiting
2
186
US, RoW
Pramipexole ER, Escitalopram
National Institute of Allergy and Infectious Diseases (NIAID), Cipla Ltd.
Major Depressive Disorder, Mild Neurocognitive Disorder, HIV
12/26
12/26
ELICIT, NCT04840199: A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.

Completed
2
44
US
Letermovir 240 MG Oral Tablet, PREVYMIS, Letermovir 480 MG Oral Tablet, Combination ART
National Institute of Allergy and Infectious Diseases (NIAID), Merck Sharp & Dohme LLC
HIV Infections, Cytomegalovirus, CMV
11/23
11/23
NCT05719441: A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission

Recruiting
2
48
US, RoW
VRC07-523LS, VRC-HIVMAB075-00-AB, PGT121.414.LS, VRC-HIVMAB0107-00-AB, Placebo, ART, Biktarvy
National Institute of Allergy and Infectious Diseases (NIAID)
Acute HIV Infection
04/28
09/28
NCT05099965: Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®)

Active, not recruiting
2
90
US
CMV-MVA Triplex, Placebo
National Institute of Allergy and Infectious Diseases (NIAID)
Cytomegalovirus Infections, HIV Infections, Vaccine
11/24
10/25
DEPTH, NCT05382208: Doxycycline for Emphysema in People Living With HIV (The Trial)

Recruiting
2
250
US
Doxycycline, Placebo
Weill Medical College of Cornell University, National Heart, Lung, and Blood Institute (NHLBI), University of California, Los Angeles, University of Iowa, University of Michigan
Emphysema, HIV
02/27
02/27
GET IT RIgHT, NCT06005610: Estradiol Therapy In Transgender Women to Research Interactions With HIV Therapy

Recruiting
2
90
US, RoW
Estradiol
National Institute of Allergy and Infectious Diseases (NIAID)
HIV I Infection
05/27
05/27
NCT06071767: Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1

Recruiting
1/2
45
US, RoW
ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62, MVA.tHIVconsv3, MVA.tHIVconsv4, Vesatolimod (VES), GS-5423, 3BNC117-LS, GS-2872, 10-1074-LS, Placebo
National Institute of Allergy and Infectious Diseases (NIAID), University of Oxford, Gilead Sciences
HIV-1-infection
04/26
04/26
NCT03705169: Pharmacokinetics and Safety of SAR441236

Terminated
1
52
US
SAR441236, Placebo
National Institute of Allergy and Infectious Diseases (NIAID), Sanofi, ModeX Therapeutics
HIV-1-infection
04/22
04/22
NCT05144386: Study of EBT-101 in Aviremic HIV-1 Infected Adults on Stable ART

Completed
1
6
US
EBT-101
Excision BioTherapeutics
HIV-1-infection
11/24
11/24
NCT06680479: Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy

Not yet recruiting
1
30
US
CH505 TF chTrimer, 3M-052-AF, Aluminum Hydroxide Suspension, Sodium Chloride for Injection
National Institute of Allergy and Infectious Diseases (NIAID), Duke University, Access to Advanced Health Institute (AAHI)
HIV-1
10/26
08/27
NCT04340596: Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption

Recruiting
1
46
US
N-803 (IL-15 Superagonist), VRC07-523LS, 10-1074
National Institute of Allergy and Infectious Diseases (NIAID), Rockefeller University, ImmunityBio, Inc.
HIV Infection
06/26
12/26
ADIPOSITY, NCT04675255: Assessing the Impact of INSTI to PI Switch on Insulin Sensitivity and Fat Metabolism

Completed
N/A
8
US
Frequently sampled glucose tolerance testing, abdominal subcutaneous adipose tissue biopsy, MRI scan to assess intrahepatic triglyceride content
Washington University School of Medicine, Janssen Scientific Affairs, LLC
HIV I Infection, Adiposity
06/23
06/23
PDP, NCT06181669: Pneumonia Direct Pilot

Recruiting
N/A
250
US
Pathogen and Host Directed testing, Respiratory Pathogen ID/AMR Enrichment Panel (Illumina), Metagenomic Next Generation Sequencing (Illumina), T2 Bacteria Panel (T2 Biosystems), T2 Resistance Panel (T2 Biosystems), Procalcitonin (Abbott), TriVerity host (Inflammatix), Host gene expression, FilmArray Pneumonia Panel (BioFire)
Duke University, National Institute of Allergy and Infectious Diseases (NIAID)
Pneumonia, Bacterial, Ventilator Associated Pneumonia
04/25
07/25
NCT00031408: Consent for Use of Stored Patient Specimens for Future Testing

Recruiting
N/A
30000
US
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
12/27
12/27
NCT05985642: Observational PIC Destination Cohort

Recruiting
N/A
30
US
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1-infection
07/29
09/29
Martin, Gina
CSIDE, NCT03619551: Conditioning SCID Infants Diagnosed Early

Recruiting
2
64
Canada, US
Busulfan, Cell processing for TCRαβ+/CD19+ depletion, CliniMACS
Michael Pulsipher, MD
SCID
08/26
08/26
NMTT, NCT02679144: Neuroblastoma Maintenance Therapy Trial

Recruiting
2
441
Canada, US
Difluoromethylornithine (DFMO), eflornithine
Giselle Sholler, Beat NB Cancer Foundation, Team Parker for Life
Neuroblastoma
02/28
02/33
NCT04696029: DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma

Recruiting
2
118
US
Difluoromethylornithine, Eflornithine, DFMO
Giselle Sholler
Medulloblastoma
03/28
03/29
NCT04301843: Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

Recruiting
2
131
Canada, US
Eflornithine, DFMO, difluoromethylornithine
Giselle Sholler, K C Pharmaceuticals Inc., Beat NB Cancer Foundation, Team Parker for Life
Neuroblastoma
10/28
10/33
PEDS-PLAN, NCT02559778: Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

Recruiting
2
500
Canada, US
Ceritinib, Zykadia, dasatinib, Sprycel, sorafenib, Nexavar, vorinostat, ZOLINZA, DFMO, Eflornithine, α-difluoromethylornithine
Giselle Sholler, Dell, Inc., Beat NB Cancer Foundation, K C Pharmaceuticals Inc., Team Parker for Life
Neuroblastoma
09/30
09/35
ATHN Transcends, NCT04398628: A Natural History Study of Non-Neoplastic Hematologic Disorders

Recruiting
N/A
3000
US
American Thrombosis and Hemostasis Network, Pfizer, Hemophilia of Georgia, Inc., Genentech, Inc., Hemab Therapeutics, CSL Behring, Sanofi, Novo Nordisk A/S
Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
06/35
12/35
Foucauld, Jean
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
VICTORION-2P, NCT05030428: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

Active, not recruiting
3
17004
Europe, Canada, Japan, US, RoW
Inclisiran sodium 300 mg, Placebo
Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease
10/27
10/27
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
NCT06142383: A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure

Terminated
2
136
Europe, Japan, US, RoW
Placebo, XXB750 Low dose, XXB750 Medium Dose, XXB750 High Dose, Sacubitril/valsartan
Novartis Pharmaceuticals
Heart Failure
11/24
11/24
NCT05562934: An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.

Completed
2
191
Europe, Japan, US, RoW
Experimental drug, Placebo
Novartis Pharmaceuticals
Resistant Hypertension
07/24
08/24
Schulz, Yvette
EPIK-P2, NCT04589650 / 2020-000561-16: Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum

Recruiting
2
205
Europe, Canada, US, RoW
Alpelisib, Placebo
Novartis Pharmaceuticals
PIK3CA-related Overgrowth Spectrum (PROS)
03/24
04/31
Khan, Hiba
NCT05758415: Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy

Active, not recruiting
3
61
Europe, US, RoW
Secukinumab, AIN457, Placebo
Novartis Pharmaceuticals
Rotator Cuff Tendinopathy
10/24
12/24
SIRIUS-SLE 2, NCT05624749 / 2022-002690-29: Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus

Recruiting
3
280
Europe, US, RoW
ianalumab, VAY736, placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Systemic Lupus Erythematosus
01/27
01/29
NCT06130540: Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR

Recruiting
1
60
Europe, US, RoW
Secukinumab, AIN457
Novartis Pharmaceuticals
Giant Cell Arteritis, Polymyalgia Rheumatica
05/25
07/25
Sampat, Swarnika
NCT04638647 / 2020-004284-98: Secukinumab Open Label Roll-over Extension Protocol

Recruiting
4
715
Europe, US, RoW
Secukinumab s.c. injection
Novartis Pharmaceuticals
Autoimmunity, Inflammation
12/27
02/28
SIRIUS-SLE 2, NCT05624749 / 2022-002690-29: Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus

Recruiting
3
280
Europe, US, RoW
ianalumab, VAY736, placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Systemic Lupus Erythematosus
01/27
01/29
NCT06130540: Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR

Recruiting
1
60
Europe, US, RoW
Secukinumab, AIN457
Novartis Pharmaceuticals
Giant Cell Arteritis, Polymyalgia Rheumatica
05/25
07/25

Download Options